Eli Lilly Changes Goal of Alzheimer Study Using Solanezumab
- Trial focused on cognitive decline will conclude this year
- Changes in activity levels a secondary endpoint in study
This article is for subscribers only.
Eli Lilly & Co. has changed the primary goal of a test of its potential Alzheimer’s disease drug, an unusual move during an ongoing study, to focus solely on whether the treatment can forestall changes that may occur early in the course of the brain disorder.
The final-stage clinical trial of solanezumab will mainly evaluate the drug’s impact on cognitive decline in patients, while removing measures of ability to perform activities of daily living, such as dressing and feeding oneself, Indianapolis-based Lilly said Tuesday in a statement. The study’s final patient was enrolled in the trial, called Expedition 3, in 2015, and the last patient visit will occur in October.